A Pediatric Phase 1 Trial and Pharmacokinetic Study of Ispinesib: A Children's Oncology Group Phase I Consortium Study

PURPOSE: To determine the maximum-tolerated dose, dose-limiting toxicities and pharmacokinetics of the kinesin spindle protein inhibitor ispinesib in pediatric patients with recurrent or refractory solid tumors. SUBJECTS AND METHODS: Ispinesib was administered as 1-hour intravenous infusion weekly ×...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Souid, Abdul-Kader, Dubowy, Ronald L., Ingle, Ashish M., Conlan, Maureen G., Sun, Junfeng, Blaney, Susan M., Adamson, Peter C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3053384/
https://ncbi.nlm.nih.gov/pubmed/20712019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.22609
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi